pretranspl
screen
potenti
organ
donor
recipi
essenti
success
solid
organ
transplant
goal
pretranspl
infecti
diseas
screen
identifi
condit
may
disqualifi
either
donor
recipi
identifi
treat
activ
infect
pretranspl
defin
risk
infect
determin
strategi
prevent
mitig
posttranspl
infect
implement
prevent
intervent
updat
vaccin
statu
although
gener
agreement
major
infect
screen
perform
variat
center
type
screen
use
action
taken
result
cours
pretranspl
evalu
recipi
evalu
infect
risk
obtain
thorough
infect
travel
histori
well
histori
anim
environment
exposur
pretranspl
period
ideal
time
detail
counsel
recipi
hisher
famili
safe
food
handl
risk
infect
associ
pet
travel
hobbi
garden
woodwork
infect
prevent
approach
includ
hand
hygien
prophylact
antimicrobi
postexposur
prophylaxi
updat
immun
address
well
varieti
pathogen
may
transmit
transplant
tabl
guidelin
pretranspl
screen
subject
sever
public
includ
consensu
confer
immunocompromis
host
societi
ich
american
societi
transplant
ast
clinic
practic
guidelin
evalu
renal
transplant
candid
astp
clinic
practic
guidelin
evalu
live
renal
transplant
donor
recommend
regard
hepat
statu
donor
summar
march
crystal
citi
meet
review
chung
feng
delmonico
addit
center
diseas
control
prevent
cdc
infecti
diseas
societi
america
idsa
american
societi
blood
marrow
transplant
asbmt
publish
guidelin
prevent
infect
hematopoiet
stem
cell
transplant
recipi
cdc
publish
guidelin
prevent
hiv
transmiss
transplant
tradit
screen
strategi
effect
case
guarante
infect
number
transmiss
incid
last
sever
year
includ
rabi
lymphocyt
choriomening
viru
west
nile
viru
wnv
hiv
hepat
c
hcv
renew
discuss
issu
surround
donor
screen
recent
form
unit
network
organ
share
uno
donor
transmiss
advisori
group
dtag
transplant
transmiss
sentinel
network
cdc
new
initi
form
address
infect
current
screen
practic
discuss
differ
screen
live
deceas
donor
review
summar
current
opinion
screen
bacteri
mycobacteri
fungal
parasit
viral
infect
donor
recipi
tabl
detail
discuss
infect
posttranspl
monitor
prophylaxi
treatment
found
section
guidelin
issu
concern
viral
serolog
donor
recipi
intertwin
discuss
togeth
given
limit
pool
donor
becom
necessari
consid
margin
candid
includ
infect
time
donat
serolog
profil
social
histori
indic
potenti
exposur
pathogen
hiv
hcv
natur
potenti
donor
infect
sever
organ
diseas
recipi
likelihood
anoth
organ
offer
patient
transplant
wait
list
import
consider
determin
accept
potenti
infect
donor
differ
screen
live
donor
deceas
donor
larg
base
differ
time
frame
evalu
must
take
place
live
donor
often
possibl
treat
activ
infect
delay
transplant
infect
resolv
signific
delay
donor
evalu
transplant
interim
evalu
may
indic
rule
recent
acquir
infect
clinic
reassess
prospect
live
donor
indic
clinic
sign
symptom
possibl
infect
occur
particularli
unexplain
febril
ill
time
initi
screen
plan
date
transplant
repeat
serolog
test
nucleic
acid
amplif
test
naat
hiv
hepat
b
viru
hbv
andor
hepat
c
viru
hcv
may
indic
sinc
antibodi
seroconvers
may
yet
occur
recent
exposur
screen
prospect
live
donor
take
place
transplant
center
includ
thorough
medic
social
histori
physic
examin
laboratori
studi
includ
serolog
test
tabl
radiograph
studi
indic
histori
procedur
perform
medic
histori
includ
assess
previou
infect
vaccin
travel
occup
exposur
well
presenc
riski
behavior
eg
drug
use
sexual
practic
incarcer
live
donor
screen
syphili
hiv
hepat
b
c
tuberculosi
via
tuberculin
ppd
skin
test
releas
assay
igra
suspici
donor
histori
addit
test
may
warrant
contrast
time
frame
deceas
donor
evalu
typic
hour
serolog
perform
laboratori
associ
organ
procur
organ
opo
refer
laboratori
oper
basi
gener
data
need
determin
donor
suitabl
time
constraint
extens
geograph
area
cover
opo
test
often
limit
serolog
method
rapid
routin
avail
sensit
test
may
avail
infect
hiv
hcv
may
difficult
diagnos
earli
stage
develop
specif
antibodi
thu
detail
social
medic
histori
donor
requir
identifi
potenti
infect
might
detect
serolog
test
furthermor
certain
infect
may
come
light
transplant
perform
result
routin
procur
cultur
blood
urin
sputum
becom
avail
increasingli
opo
util
rapid
molecular
test
particularli
potenti
donor
rapid
detect
viral
genet
materi
naat
particularli
viral
infect
hcv
hbv
hiv
test
certain
pathogen
particular
geograph
signific
trypanosoma
cruzi
chaga
diseas
wnv
may
perform
opo
deceas
donor
uncertain
infect
risk
use
inform
consent
recipi
includ
risk
infect
transmiss
evalu
detail
reveal
activ
bacteri
infect
present
live
donor
infect
respiratori
tract
urinari
tract
focal
site
thoroughli
treat
document
resolut
infect
prior
donat
potenti
kidney
donor
urinari
tract
infect
investig
rule
upper
tract
involv
potenti
donor
histori
suspicion
prior
bloodstream
infect
thorough
investig
perform
insur
target
organ
seed
syphili
may
latent
asymptomat
requir
therapi
time
permit
syphili
rare
transmit
transplant
contraind
organ
donat
recipi
treat
posttranspl
appropri
cours
benzathin
penicillin
standard
regimen
late
latent
syphili
would
appropri
situat
eg
three
weekli
dose
million
unit
intramuscular
benzathin
penicillin
deceas
donor
may
harbor
known
unsuspect
bacteri
infect
evalu
review
medic
record
detail
histori
donor
famili
temperatur
chart
radiographi
cultur
avail
blood
cultur
obtain
rule
occult
donor
bacteremia
bacteremia
virul
organ
staphylococcu
aureu
pseudomona
aeruginosa
may
result
earli
posttranspl
sepsi
mycot
aneurysm
format
site
vascular
anastomos
recipi
although
review
bacterem
donor
found
evid
transmiss
recipi
given
antimicrobi
therapi
mean
day
posttranspl
prudent
employ
longer
cours
therapi
recipi
eg
week
donor
known
bacterem
virul
organ
gener
reason
treat
recipi
allograft
deceas
donor
nonbacterem
local
infect
involv
transplant
organ
except
mening
occult
bacteremia
frequent
occur
iii
organ
success
transplant
donor
bacteri
mening
appropri
antimicrobi
therapi
administ
donor
recipi
lung
transplant
deserv
special
attent
donor
bacteri
colon
common
lung
contact
extern
environ
mouth
upper
airway
site
colon
multipl
organ
donor
bronchoscopi
cultur
perform
time
evalu
andor
procur
allow
administr
antibiot
direct
colon
organ
prevent
invas
infect
recipi
iii
allograft
contamin
may
occur
procur
process
rubin
recommend
treatment
recipi
organ
isol
perfus
organ
transplant
medium
cite
risk
mycot
aneurysm
format
although
cultur
contamin
must
consid
well
antibiot
administ
least
day
bacilli
aureu
candida
speci
shorter
cours
therapi
may
consid
less
virul
organ
iii
recent
studi
kidney
preserv
fluid
contamin
candida
speci
eight
recipi
demonstr
risk
mycot
aneurysm
ruptur
mitig
appropri
antifung
therapi
mycobacterium
tuberculosi
transmit
transplant
donor
transmiss
account
approxim
report
posttranspl
tb
case
review
patient
singh
paterson
potenti
live
donor
ppd
test
perform
tuberculin
skin
test
endem
area
tb
igra
test
either
test
posit
addit
test
perform
rule
activ
infect
iii
symptom
chest
radiograph
find
suggest
activ
diseas
sputum
afb
cultur
perform
chest
comput
tomographi
ct
may
help
assess
adenopathi
urin
microscopi
afb
cultur
excretori
urogram
abdomin
ct
scan
may
use
prospect
kidney
donor
sign
symptom
activ
diseas
chest
radiograph
normal
sputum
afb
cultur
manag
prospect
live
donor
latent
tb
infect
ltbi
differ
area
differ
endem
delay
transplant
live
donor
treat
ltbi
isoniazid
month
rifampin
month
appropri
anoth
suitabl
donor
avail
tb
endem
area
mani
donor
ltbi
may
difficult
avoid
use
infect
donor
one
cohort
studi
endem
area
demonstr
benefit
treat
prospect
live
donor
ltbi
prior
transplant
isoniazid
prophylaxi
recipi
option
control
studi
need
determin
efficaci
practic
deceas
donor
time
allow
tuberculin
skin
test
igra
yet
logist
practic
situat
donor
activ
tuberculosi
clinic
possibl
util
case
potenti
donor
known
recent
ppd
skin
test
convers
transplant
approach
caution
due
risk
dissemin
recipi
donor
histori
posit
ppd
without
evid
activ
diseas
accept
warrant
consider
treatment
recipi
isoniazid
inh
iii
activ
system
fungal
infect
donor
contraind
transplant
endem
mycos
particular
may
present
dormant
form
transmiss
histoplasmosi
transplant
describ
case
appear
result
reactiv
past
infect
recipi
mani
individu
midwestern
unit
state
calcifi
pulmonari
hilar
splenic
granulomata
may
visibl
residua
old
histoplasma
infect
radiograph
sign
tradit
consid
contraind
donat
iii
transmiss
coccidioidomycosi
lung
transplant
report
southwestern
unit
state
although
reactiv
coccidioidomycosi
recipi
appear
far
common
yet
uniform
recommend
donor
screen
endem
mycos
emerg
toxoplasmosi
major
concern
particularli
heart
transplant
recipi
heart
highest
risk
develop
activ
toxoplasmosi
posttranspl
toxoplasmosi
also
rare
transmit
liver
kidney
recipi
donor
seroposit
contraind
heart
donat
allow
appropri
prophylaxi
administ
recipi
routin
prophylaxi
pneumocysti
jiroveci
effect
prevent
toxoplasmosi
may
negat
need
serolog
test
area
low
preval
screen
donor
toxoplasma
routin
perform
noncardiac
donor
may
part
screen
panel
center
transmiss
chaga
diseas
cruzi
transplant
signific
problem
endem
area
south
latin
america
rare
report
unit
state
routin
screen
yet
mandat
unit
state
discuss
issu
found
parasitolog
section
guidelin
cmv
serolog
statu
donor
recipi
import
predictor
posttranspl
infect
cmv
seroneg
recipi
cmv
seroposit
donor
organ
highest
risk
develop
cmv
recurr
cmv
cmv
consequ
donor
recipi
test
cmv
infect
use
commonli
avail
serolog
techniqu
contraind
transplant
statu
indic
intens
monitor
prevent
strategi
posttranspl
donorrecipi
pair
lower
risk
cmv
infect
seroposit
recipi
regardless
donor
statu
risk
cmv
reactiv
usual
receiv
either
prophylaxi
preemptiv
monitor
therapi
mani
differ
protocol
use
full
discuss
cmv
prevent
method
found
anoth
section
posttranspl
lymphoprolif
diseas
ptld
fear
complic
transplant
highest
ptld
risk
ebv
seroneg
recipi
ebv
seroposit
graft
commonli
occur
pediatr
recipi
ptld
also
develop
seroposit
recipi
influenc
augment
immunosuppress
awar
pretranspl
serolog
target
highest
risk
group
close
monitor
preemptiv
intervent
decreas
immunosuppress
pediatr
transplant
center
ebv
serolog
perform
donor
recipi
approxim
adult
seroposit
ebv
ebv
serolog
avail
adult
donor
presum
seroposit
herpesvirus
clinic
import
transplant
recipi
includ
herp
simplex
viru
viru
vzv
human
kshv
hsv
screen
perform
center
wherea
center
administ
univers
antivir
prophylaxi
least
first
month
posttranspl
primari
varicella
infect
posttranspl
fatal
vzv
screen
recipi
extrem
import
vaccin
seroneg
recipi
pretranspl
possibl
iii
addit
knowledg
vzv
serostatu
transplant
import
manag
vzv
exposur
recent
awar
possibl
role
cofactor
cmv
effect
fungal
infect
possibl
allograft
dysfunct
led
increas
interest
virus
sinc
almost
adult
seroposit
howev
donor
recipi
screen
virus
gener
recommend
whether
screen
would
help
pediatr
transplant
program
yet
unknown
agent
kaposi
sarcoma
reactiv
transplant
may
transmit
transplant
may
also
associ
lymphoprolif
diseas
seropreval
vari
wide
accord
popul
studi
optim
strategi
prevent
reactiv
defin
thu
definit
recommend
pretranspl
screen
made
present
time
donor
recipi
test
hepat
b
use
standard
serolog
techniqu
complex
issu
surround
hbv
transplant
discuss
detail
hepat
section
guidelin
donor
screen
usual
includ
least
hepat
b
surfac
antigen
hbsag
hbv
core
antibodi
hbcab
use
perform
igg
igm
donor
hbsag
posit
posit
indic
activ
hbv
infect
hbsag
neg
posit
person
may
window
period
donor
gener
util
although
center
use
donor
recipi
evid
immun
hepat
b
hbsab
andor
intens
posttranspl
prophylaxi
monitor
isol
hbsab
posit
usual
indic
prior
vaccin
resolv
infect
gener
consid
risk
hbv
transmiss
complex
question
use
hbsag
neg
posit
donor
donor
may
repres
either
test
isol
hbcab
posit
persist
hbv
infect
latter
signific
risk
transmiss
hbv
liver
transplant
recipi
therefor
liver
often
util
past
howev
becom
common
transplant
liver
hbcab
posit
donor
intens
posttranspl
prophylaxi
risk
transmiss
nonhepat
recipi
appear
low
zero
risk
diminish
pretranspl
hbv
vaccin
recipi
center
restrict
use
organ
situat
andor
vaccin
recipi
would
util
posttranspl
prophylaxi
hepat
b
immun
globulin
hbig
andor
lamivudin
transplant
nonimmun
recipi
possibl
offer
organ
prudent
vaccin
seroneg
transplant
candid
hbv
vaccin
although
respons
vaccin
patient
organ
diseas
may
suboptim
higher
addit
dose
strategi
may
requir
iii
donor
level
provid
help
inform
design
prophylact
strategi
even
result
receiv
transplant
detail
recommend
posttranspl
prophylaxi
found
chung
et
al
hepat
section
guidelin
recipi
screen
hbv
help
posttranspl
manag
patient
undergo
liver
transplant
liver
diseas
due
hbv
varieti
posttranspl
protocol
prevent
reactiv
hbv
mani
util
hbig
nonhepat
transplant
hbsag
posit
recipi
controversi
earli
day
kidney
transplant
transplant
perform
recipi
develop
earli
fulmin
liver
diseas
greater
number
develop
chronic
liver
diseas
maintain
asymptomat
statu
mani
year
despit
evid
activ
viral
replic
period
time
hbsag
posit
statu
consid
contraind
nonhepat
transplant
effect
therapi
lamivudin
adefovir
tenofovir
avail
appear
theoret
possibl
transplant
recipi
safe
although
antivir
resist
may
becom
issu
iii
hcv
infect
frequent
chronic
donor
recipi
test
presenc
hcv
via
standard
serolog
techniqu
hcv
major
indic
liver
transplant
although
hcv
recurr
common
posttranspl
patient
liver
graft
surviv
significantli
wors
pretranspl
diagnos
hcv
seroposit
renal
transplant
candid
higher
risk
liver
diseas
sepsi
transplant
hcv
seroneg
counterpart
compar
transplant
altern
balanc
benefit
often
fall
side
transplant
case
role
pretranspl
viral
load
reduct
studi
strategi
manag
hcv
recipi
discuss
detail
later
section
hepat
c
donor
tradit
consid
dilemma
high
risk
transmiss
hcv
transplant
organ
posit
donor
indic
activ
viral
replic
associ
higher
risk
transmiss
often
inform
avail
time
frame
requir
util
deceas
donor
risk
transmiss
neg
hcv
antibodi
posit
donor
yet
fulli
defin
futur
rapid
molecular
test
like
increasingli
perform
time
frame
need
donor
evalu
crystal
citi
meet
report
increas
mortal
morbid
transplant
liver
kidney
donor
versu
donor
recipi
howev
larg
studi
abbott
colleagu
adult
renal
transplant
recipi
demonstr
independ
risk
increas
mortal
donor
even
subgroup
recipi
compar
remain
wait
list
surviv
advantag
receiv
kidney
hcv
donor
thu
surviv
kidney
hcv
donor
less
seen
set
hcv
neg
donor
appear
associ
better
surviv
remain
dialysi
recent
year
use
hcv
organ
transplant
recipi
also
studi
sometim
accept
result
survey
lung
transplant
program
report
util
hcv
seroposit
donor
mani
case
restrict
hcv
seroposit
recipi
survey
heart
transplant
program
reveal
center
use
hcv
donor
statu
andor
hcv
transplant
candid
center
report
never
use
hcv
seroposit
donor
survey
center
report
list
hcv
candid
heart
transplant
howev
one
seri
identifi
excess
rapidli
progress
cholestat
hepat
increas
mortal
overal
recipi
hcv
donor
heart
immunosuppress
whether
specif
immunosuppress
regimen
prefer
situat
requir
studi
event
whenev
hcv
seroposit
donor
util
stringent
inform
consent
advis
recent
transmiss
event
proven
hcv
transmit
multipl
organ
tissu
transplant
recipi
seroneg
donor
time
infect
antibodi
product
vari
individu
although
viral
rna
may
present
much
earlier
acut
infect
efficaci
feasibl
naat
confirmatori
hcv
rna
test
investig
hope
decreas
risk
transmiss
donor
recipi
donor
tradit
util
transplant
due
known
risk
transmiss
recipi
serolog
requir
potenti
donor
least
serolog
recipi
rare
unit
state
posit
screen
serolog
often
western
blot
test
obtain
confirm
posit
screen
test
either
potenti
live
donor
risk
factor
hiv
exposur
neg
hiv
serolog
molecular
viral
test
obtain
test
becom
posit
prior
develop
posit
antibodi
test
avail
naat
hiv
also
desir
deceas
donor
potenti
exposur
identifi
social
histori
recent
report
hiv
transmiss
organ
donor
underscor
risk
transmiss
donor
window
period
infect
prior
develop
antibodi
although
previous
consid
contraind
transplant
hiv
seroposit
recipi
receiv
renew
attent
mani
patient
hiv
highli
activ
antiretrovir
therapi
haart
regimen
live
longer
far
less
immunocompromis
case
organ
failur
rather
hiv
condit
multicent
trial
evalu
feasibl
transplant
individu
updat
result
includ
graft
patient
surviv
data
indic
transplant
well
toler
meticul
clinic
care
care
attent
pharmacokinet
set
signific
drug
interact
immunosuppress
agent
haart
complex
issu
involv
fulli
discuss
hiv
section
guidelin
endem
certain
part
world
includ
caribbean
japan
often
asymptomat
howev
infect
progress
year
decad
associ
myelopathytrop
spastic
paraparesi
hamtsp
adult
leukemialymphoma
atl
progress
occur
seroposit
individu
endem
region
respect
viru
serolog
difficult
distinguish
although
associ
diseas
process
less
certain
pcr
assay
use
distinguish
ii
seroposit
donor
often
util
although
use
donor
could
consid
situat
particularli
older
recipi
appropri
inform
consent
iii
expert
recommend
widespread
use
donor
cite
review
recipi
uno
registri
receiv
transplant
posit
donor
organ
transplant
diseas
report
recipi
median
followup
month
howev
report
spain
transmiss
rapid
develop
myelopathi
recipi
suggest
exercis
caution
use
donor
endem
area
recipi
often
test
antibodi
although
littl
known
cours
infect
follow
solid
organ
transplant
case
reactiv
observ
seri
japanes
seroposit
recipi
undergo
renal
transplant
recent
year
increasingli
recogn
emerg
viral
infect
impact
transplant
transmiss
unusu
sever
present
recipi
wnv
flaviviru
caus
meningoenceph
recent
appear
unit
state
fall
cdc
investig
transmiss
wnv
singl
donor
four
organ
recipi
report
addit
report
transmiss
blood
transfus
liver
transplant
appear
unclear
yet
magnitud
risk
transmiss
pattern
wnv
activ
chang
yearli
basi
serolog
pcr
wnv
avail
prudent
avoid
donor
unexplain
febril
ill
unexplain
mental
statu
chang
unexplain
mening
enceph
sinc
juli
us
blood
bank
product
test
wnv
use
investig
naat
perform
specif
center
fall
us
health
resourc
servic
administr
hrsa
issu
guidanc
statement
regard
donor
wnv
recommend
test
prospect
live
donor
naat
close
time
transplant
avoid
donor
form
unexplain
confirm
wnv
enceph
heighten
clinic
suspicion
part
treat
clinician
febril
ill
occur
shortli
transplant
naat
pose
logist
challeng
uno
region
mandat
donor
screen
also
concern
fals
posit
naat
may
result
loss
noninfect
organ
net
loss
life
particularli
liver
heart
candid
wait
list
region
canada
prospect
donor
test
wnv
naat
lymphocyt
choriomening
viru
lcmv
arenaviru
report
sever
cluster
transmiss
multipl
organ
recipi
fatal
infect
one
cluster
outbreak
origin
new
pet
hamster
donor
home
strikingli
howev
donor
lcmv
serolog
neg
rais
question
kind
screen
measur
could
detect
prevent
transmiss
cdc
issu
interim
guidelin
minim
risk
lcmv
relat
pet
rodent
investig
lcmv
outbreak
involv
molecular
diagnost
test
dozen
pathogen
establish
valu
cooper
commun
opo
transplant
center
public
health
depart
cdc
investig
unusu
clinic
scenario
transplant
recipi
infect
suspect
blueprint
investig
led
increas
awar
infect
comprehens
report
system
introduc
cdc
recent
report
transmiss
new
relat
arenaviru
multipl
recipi
also
highlight
use
new
molecular
technolog
identif
unknown
pathogen
rabi
anoth
potenti
fatal
infect
recipi
transplant
donor
die
cerebr
hemorrhag
acquir
rapidli
progress
neurolog
ill
found
rabi
retrospect
donor
found
recent
bat
bite
us
rabi
transmit
commonli
bite
scratch
saliva
exposur
bat
raccoon
skunk
fox
rabi
lcmv
case
rais
question
whether
donor
evalu
includ
inform
exposur
anim
bite
environment
exposur
supplement
alreadi
detail
inform
obtain
highli
fatal
natur
rabi
infect
clinician
encourag
avoid
donor
even
small
possibl
rabi
present
new
respiratori
pathogen
report
caus
sever
diseas
rapid
intern
spread
sever
acut
respiratori
syndrom
sar
found
due
previous
undescrib
coronaviru
nosocomi
household
transmiss
least
affect
patient
requir
mechan
ventil
least
one
transplant
recipi
die
sar
transmiss
transplant
theoret
possibl
extent
risk
unknown
current
principl
donor
recipi
select
would
like
exclud
patient
recent
acut
ill
meet
sar
criteria
howev
consequ
remot
histori
sar
subclin
infect
unknown
screen
tool
potenti
adult
pediatr
donor
propos
expert
toronto
one
major
center
outbreak
took
account
risk
sar
transmiss
donor
hospit
well
donor
symptom
travel
contact
histori
anoth
sar
outbreak
occur
similarli
transmit
emerg
viru
donor
screen
algorithm
would
use
new
emerg
potenti
communic
agent
may
aris
may
affect
donor
accept
recipi
activ
transplant
list
advis
avoid
transplant
involv
individu
potenti
communic
infect
inadequ
inform
exist
provid
appropri
recommend
regard
precautionari
measur
addit
screen
test
emerg
pathogen
sensit
test
known
pathogen
may
propos
guidelin
committe
futur
committe
consid
feasibl
test
well
risk
test
result
could
lead
util
donor
organ
otherwis
might
recipi
transplant
recipi
risk
infect
relat
complic
organ
failur
patient
await
renal
transplant
may
infect
hemodialysi
periton
dialysi
access
site
cathet
complic
andor
urinari
infect
candid
await
liver
transplant
risk
aspir
pneumonia
spontan
bacteri
periton
urinari
tract
infect
infect
associ
intraven
cathet
candid
await
heart
transplant
may
infect
relat
either
indwel
intraven
cathet
ventricular
assist
devic
vad
util
bridg
transplant
addit
heart
candid
also
risk
pneumonia
set
congest
heart
failur
debilit
ventricular
vad
infect
treat
prior
transplant
although
complet
erad
may
possibl
transplant
infect
common
vad
larg
foreign
bodi
may
place
three
month
longer
portal
entri
frequent
abdomin
wall
exit
site
drivelin
may
exit
site
drainag
local
infect
proxim
infect
vad
pocket
bacteremia
andor
endocard
caus
organ
includ
staphylococci
aureu
aerob
bacilli
yeast
protract
antibacteri
therapi
may
lead
candida
superinfect
infect
contraind
transplant
howev
total
remov
vad
time
transplant
combin
appropri
posttranspl
antibiot
therapi
often
cur
screen
lung
transplant
recipi
includ
assess
colon
airway
flora
care
review
previou
pulmonari
infect
cystic
fibrosi
patient
may
colon
multiresist
strain
pseudomona
andor
burkholderia
cepacia
well
organ
aureu
alcaligen
stenotrophomona
aspergillu
scedosporium
knowledg
pretranspl
colon
flora
assist
decis
regard
individu
peritranspl
prophylact
antimicrobi
regimen
controversi
whether
patient
colon
burkholderia
exclud
receiv
lung
transplant
molecular
type
burkholderia
isol
promis
method
may
use
defin
risk
futur
genomovar
burkholderia
cenocepacia
associ
highest
risk
poor
outcom
transplant
patient
ppd
tuberculin
skin
test
perform
prior
transplant
posit
skin
test
histori
activ
tuberculosi
undergo
addit
screen
rule
activ
diseas
see
recent
avail
igra
gener
interest
particularli
regard
patient
receiv
bacillu
bcg
vaccin
igra
assay
potenti
distinguish
ppd
posit
relat
bcg
relat
ltbi
isoniazid
hepatotox
appear
less
problem
origin
thought
transplant
candid
recipi
therefor
patient
histori
posit
ppd
radiograph
evid
prior
tb
previou
treatment
consid
isoniazid
prophylaxi
prophylaxi
start
patient
transplant
wait
list
complet
transplant
donor
organ
becom
avail
least
month
isoniazid
administ
prophylaxi
cours
month
complet
transplant
transplant
urgent
need
isoniazid
poorli
toler
prior
transplant
prophylaxi
begin
shortli
transplant
altern
isoniazid
prophylaxi
popul
true
allergi
sever
intoler
isoniazid
clearli
defin
rifampin
anoth
option
prophylaxi
signific
drug
interact
calcineurin
inhibitor
util
cours
complet
prior
transplant
transplant
candid
clinic
histori
radiograph
andor
cultur
suggest
infect
tb
nontubercul
mycobacteria
thorough
evalu
activ
diseas
perform
may
includ
ct
scan
bronchoscopi
test
deem
clinic
necessari
mycobacteri
infect
optim
treat
document
microbiolog
radiograph
resolut
transplant
consid
pretranspl
colon
fungi
aspergillu
common
lung
transplant
recipi
particularli
cystic
fibrosi
patient
colon
prompt
rigor
evalu
exclud
activ
infect
although
posttranspl
aspergillosi
fear
complic
transplant
clinician
gener
reli
posttranspl
preemptiv
prophylact
strategi
rather
pretranspl
antifung
therapi
colon
patient
pretranspl
candid
invas
fungal
infect
rather
colon
treat
least
radiograph
clinic
microbiolog
resolut
order
minim
risk
infect
posttranspl
iii
pretranspl
screen
endem
mycos
use
area
endem
coccidioidomycosi
pretranspl
histori
activ
diseas
andor
seroposit
may
prompt
lifelong
azol
prophylaxi
pretranspl
screen
histoplasmosi
limit
valu
sinc
latent
histoplasmosi
may
present
neg
serolog
iii
instead
heighten
awar
possibl
histoplasmosi
import
investig
posttranspl
febril
ill
patient
endem
area
patient
endem
area
travel
extend
period
time
endem
area
strongyloidiasi
includ
tropic
countri
part
southeastern
unit
state
risk
develop
dissemin
strongyloidiasi
transplant
although
center
screen
stool
ova
parasit
examin
expert
favor
screen
serolog
strongyloid
much
sensit
stool
exam
iii
seroposit
patient
short
cours
ivermectin
thiabendazol
indic
pretranspl
although
random
data
lack
regimen
util
includ
ivermectin
mgkg
daili
day
clinician
recommend
repeat
cours
one
week
later
discuss
toxoplasma
serolog
import
heart
recipi
seroneg
heart
recipi
seroposit
donor
receiv
prophylaxi
chaga
diseas
parasit
infect
fulli
discuss
parasit
infect
section
guidelin
activ
primari
infect
virus
cmv
ebv
hbv
time
transplant
uncommon
nonetheless
activ
viral
infect
detect
potenti
recipi
transplant
like
delay
infect
resolv
order
allow
develop
natur
immun
prior
transplant
immunosuppress
iii
recommend
also
extend
candid
present
transplant
clinic
symptom
suggest
acut
viral
infect
chanc
exposur
hiv
pretranspl
potenti
recipi
hiv
molecular
detect
test
well
hiv
antibodi
test
iii
viral
screen
donor
recipi
discuss
detail
pretranspl
evalu
present
import
opportun
updat
potenti
recipi
immun
sinc
mani
vaccin
effect
administ
prior
onset
transplant
immunosuppress
detail
immun
recommend
summar
later
section
guidelin
candid
ideal
immun
varicella
prior
transplant
howev
transplant
expect
immin
may
best
withhold
varicella
vaccin
live
attenu
vaccin
iii
zoster
vaccin
also
live
vaccin
current
licens
older
adult
immunocompromis
data
await
regard
whether
pretranspl
zoster
vaccin
prevent
posttranspl
zoster
reactiv
present
time
would
appear
reason
administ
zoster
vaccin
transplant
candid
meet
current
criteria
vaccin
transplant
expect
within
week
yearli
influenza
vaccin
administ
transplant
candid
vaccin
household
contact
health
care
worker
also
import
immunocompromis
patient
may
mount
optim
antibodi
respons
vaccin
hepat
b
vaccin
seri
ideal
administ
pretranspl
seroneg
individu
especi
potenti
donor
may
found
hbsag
neg
hbcab
posit
clinician
advoc
acceler
cours
eg
month
rather
tradit
schedul
dose
month
data
await
iii
respons
vaccin
diminish
organ
diseas
earli
vaccin
patient
may
eventu
requir
transplant
indic
enhanc
potenc
formul
dialysi
patient
other
avail
patient
advanc
liver
diseas
particularli
high
risk
fulmin
hepat
receiv
hepat
vaccin
vaccin
like
effect
administ
earli
liver
diseas
combin
hepat
b
vaccin
immunogen
data
await
transplant
candid
recipi
mmr
vaccin
contain
live
viru
patient
born
presum
natur
immun
patient
born
receiv
second
dose
mmr
vaccin
receiv
second
dose
given
pre
rather
posttranspl
iii
pneumococc
polysaccharid
vaccin
ideal
also
administ
transplant
candid
age
receiv
within
past
year
iii
pleas
see
immun
section
pediatr
recommend
toxoid
td
booster
prefer
tdap
pertussi
vaccin
administ
potenti
adult
recipi
td
booster
within
year
iii
prevent
strategi
infect
limit
medic
vaccin
thorough
educ
transplant
recipi
famili
import
prevent
tool
pretranspl
class
print
materi
help
includ
inform
handwashinghand
hygien
environment
exposur
activ
avoid
food
safeti
handl
foodborn
pathogen
pet
travel
also
help
patient
gener
idea
infect
transplant
patient
suscept
prevent
strategi
use
particular
center
pretranspl
screen
donor
recipi
afford
opportun
assess
safeti
transplant
determin
prophylaxi
prevent
strategi
util
posttranspl
detect
fulli
treat
activ
infect
potenti
recipi
prior
transplant
updat
vaccin
statu
potenti
recipi
educ
patient
famili
prevent
measur
futur
advanc
like
includ
increas
use
rapid
molecular
diagnost
test
possibl
addit
test
emerg
pathogen
averi
r
researchgr
support
roch
pharmaceut
viropharma
medimmun
fischer
sa
author
noth
disclos
